NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $16.85 +0.36 (+2.18%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eton Pharmaceuticals Stock (NASDAQ:ETON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$15.51▼$17.1150-Day Range$11.47▼$16.8552-Week Range$3.18▼$18.41Volume197,274 shsAverage Volume179,367 shsMarket Capitalization$451.88 millionP/E RatioN/ADividend YieldN/APrice Target$27.67Consensus RatingBuy Company OverviewEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Read More… Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreETON MarketRank™: Eton Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 387th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($0.14) to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -76.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -76.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 28.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.82% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 17.07%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.82% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 17.07%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.85 News SentimentEton Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Eton Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows1 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.89% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ETON Stock News HeadlinesEton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)April 28 at 7:00 AM | globenewswire.comB.Riley Financial Remains a Buy on Eton Pharmaceuticals (ETON)April 17, 2025 | markets.businessinsider.comMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.April 30, 2025 | Behind the Markets (Ad)Eton Pharmaceuticals management to meet virtually with B. RileyApril 12, 2025 | markets.businessinsider.comEton Pharmaceuticals management to meet with Craig HallumApril 10, 2025 | markets.businessinsider.comEton Pharmaceuticals out-licenses international rights to IncrelexApril 2, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Their Buy Rating for Eton Pharmaceuticals (ETON)April 2, 2025 | markets.businessinsider.comESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatmentApril 1, 2025 | finance.yahoo.comSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $13.32 on January 1st, 2025. Since then, ETON shares have increased by 26.5% and is now trading at $16.85. View the best growth stocks for 2025 here. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) announced its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.02). The firm earned $11.65 million during the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative trailing twelve-month return on equity of 36.29%. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Top institutional shareholders of Eton Pharmaceuticals include Westside Investment Management Inc. (1.84%) and Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Opaleye Management Inc and Sean Brynjelsen. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CymaBay Therapeutics (CBAY), Arista Networks (ANET), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings3/18/2025Today4/30/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$27.67 High Stock Price Target$33.00 Low Stock Price Target$24.00 Potential Upside/Downside+67.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-940,000.00 Net Margins-15.81% Pretax Margin-15.30% Return on Equity-36.29% Return on Assets-16.84% Debt Debt-to-Equity RatioN/A Current Ratio1.51 Quick Ratio1.41 Sales & Book Value Annual Sales$39.01 million Price / Sales11.39 Cash Flow$0.00 per share Price / Cash Flow4,502.79 Book Value$0.60 per share Price / Book27.62Miscellaneous Outstanding Shares26,818,000Free Float22,172,000Market Cap$444.37 million OptionableOptionable Beta1.34 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ETON) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.